Surgalign (SRGA) Stock Forecast, Price Target & Predictions
SRGA Stock Forecast
Surgalign stock forecast is as follows: an average price target of $3.50 (represents a 1813.61% upside from SRGA’s last price of $0.18) and
SRGA Price Target
Surgalign Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Dec 21, 2022 | - | H.C. Wainwright | $3.50 | $1.36 | 157.35% | 1813.61% |
10
Surgalign Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $0.18 | $0.18 | $0.18 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Surgalign Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
SRGA | Surgalign | $0.18 | $3.50 | 1844.44% | - |
APYX | Apyx Medical | $1.16 | $8.50 | 632.76% | Buy |
AZYO | Elutia | $1.49 | $10.25 | 587.92% | Buy |
INGN | Inogen | $11.33 | $26.00 | 129.48% | Buy |
CVRX | CVRx | $7.85 | $15.83 | 101.66% | Buy |
OFIX | Orthofix Medical | $16.76 | $31.00 | 84.96% | - |
ESTA | Establishment Labs | $44.20 | $78.00 | 76.47% | Buy |
FNA | Paragon 28 | $7.39 | $11.50 | 55.62% | Buy |
HYPR | Hyperfine | $1.04 | $1.60 | 53.85% | Buy |
SIBN | SI-BONE | $15.73 | $20.00 | 27.15% | Buy |
AVNS | Avanos Medical | $24.00 | $27.00 | 12.50% | Hold |
SRDX | Surmodics | $39.36 | $39.50 | 0.36% | Buy |
HSCS | Heart Test Laboratories | $3.04 | $3.00 | -1.32% | Buy |
BVS | Bioventus | $11.17 | $7.50 | -32.86% | Buy |
SRGA Forecast FAQ
Will Surgalign stock go up soon?
According to Wall Street analysts' prediction for SRGA stock, the company can go up by 1813.61% (from the last price of $0.183 to the average price target of $3.5), up by 1813.61% based on the highest stock price target, and up by 1813.61% based on the lowest stock price target.
Can Surgalign stock reach $0?
SRGA's average twelve months analyst stock price target of $3.5 supports the claim that Surgalign can reach $0 in the near future.